Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sentynl gains US rights to Mereo's Phase III alvelestat for alpha-1 lung disease

11 August 2026 · By · Wire by Fusion42

Published

11 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 23 August 2026 · Fusion42 review

Sentynl Therapeutics has secured exclusive US commercial rights and global manufacturing rights to Mereo BioPharma's Phase III-ready oral drug alvelestat for treating alpha-1 antitrypsin deficiency-associated lung disease, with a Phase III trial planned for early 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your rare disease drug portfolio just got a US commercial lifeline with Sentynl’s rights deal for alvelestat. Prepare for a crowded market where an oral alternative to protein therapies could shift patient preference and payer coverage.

◆ Coverage

1 source · 11 Aug 2026

◆ Related on Wire

◆ Topics

Biotechrare-diseaseoral-therapyalpha-1-antitrypsindrug-licensingphase-iii